SC
CRL icon

SummitTX Capital’s Charles River Laboratories CRL Stock Holding History

SummitTX Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Buy
+14,458
New +$2.57M 0.08% 251
2026
Q1 		– Sell
-13,066
Closed -$2.61M – 811
2025
Q4 		$2.61M Buy
+13,066
New +$2.37M 0.08% 267

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

SummitTX Capital's CRL Position: Q2 2026 in Review

SummitTX Capital opened a new position in Charles River Laboratories (CRL) in Q2 2026: 14,458 shares worth $3.28M. The stake represents 0.08% of the portfolio and ranks #251 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in CRL as recently as Q4 2025.

SummitTX Capital first reported a position in CRL in Q4 2025 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • SummitTX Capital held 14,458 shares of Charles River Laboratories worth $3.28M as of Q2 2026.
  • Charles River Laboratories was a new SummitTX Capital position in Q2 2026.
  • Charles River Laboratories made up 0.08% of SummitTX Capital's portfolio in Q2 2026, its #251 holding.
  • SummitTX Capital first reported a position in Charles River Laboratories in Q4 2025 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.